Subclinical Left Ventricular Longitudinal Systolic Dysfunction in Hypertension With No Evidence of Heart Failure

Nishikage, Tomoko; Nakai, Hiromi; Lang, Roberto M.; Takeuchi, Masaaki

doi:10.1253/circj.72.189

Cited by 50 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although early stage hyperthyroid cardiomyopathy usually is associated with normal LVEF, radial shortening does not always guarantee normal LV systolic function [20]. In our study, eight of ten in T 4 alone rats showed more deteriorated LV S long despite similar EF and FS compared with control.…”

Section: Interstitial Connective Tissuecontrasting

confidence: 69%

“…In our study, eight of ten in T 4 alone rats showed more deteriorated LV S long despite similar EF and FS compared with control. Since longitudinal shortening is governed by longitudinal subendocardial fibers, which are more vulnerable to myocardial ischemia, assessment of LV longitudinal function based on strain echocardiography may be a sensitive marker for detecting subclinical alterations in LV systolic performance [20,21]. Analysis with speckle tracking strain imaging measures wall motion velocities relatively irrespective of volume, contrary to EF, and has been validated for the evaluation of longitudinal LV function [21,22].…”

Section: Interstitial Connective Tissuementioning

confidence: 99%

See 1 more Smart Citation

Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy

et al. 2012

View full text Add to dashboard Cite

Section: Interstitial Connective Tissuecontrasting

confidence: 69%

Section: Interstitial Connective Tissuementioning

confidence: 99%

Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy

et al. 2012

View full text Add to dashboard Cite

“…Several investigators have suggested that patients with HFPSF do not necessary have normal S function. 35,36 Our present result may have implications for the optimal medical therapy for patients with HFPSF. As mentioned, limited data are available with respect to the medical treatment of the HFPSF patients.…”

Section: Figmentioning

confidence: 68%

Elevated E/E' Predicts Prognosis in Congestive Heart Failure Patients With Preserved Systolic Function

Okura

Kubo

Asawa

et al. 2009

Circ J

View full text Add to dashboard Cite

Background Although approximately 50% of heart failure patients are reported as heart failure with preserved left ventricular systolic function (HFPSF), echocardiographic prognostic predictors have not been well investigated. Recently, the tissue Doppler-derived index, the ratio of the early transmitral flow velocity and the early mitral annular velocity (E/E'), was reported as useful in predicting prognosis of patients with heart diseases. The purpose of this study was to investigate whether E/E' predicts prognosis in HFPSF. Methods and Results A total of 50 patients with HFPSF (ejection fraction >50%) were consecutively enrolled and studied. Echocardiographic examination was performed on admission and repeated after optimized medical therapy. Cardiac events were defined as death and unplanned hospitalization because of congestive heart failure. Cardiac event-free survival curves from patients with E/E' >15 and E/E' ≤15 at baseline did not differ. On the other hand, patients with E/E' >15 after medical therapy showed significantly lower cardiac event-free survival than patients with E/E' ≤15 (log-rank, P=0.005). By multivariate logistic regression analysis, E/E' >15 after medical therapy was the only independent predictor of cardiac events (P=0.037, risk ratio=6.1, 95% confidence interval: 1.12-33.3) in patients with HFPSF. Conclusions Elevated E/E' after optimized medical therapy may be useful in predicting cardiac events in patients with HFPSF. (Circ J 2009; 73: 86 -91)

show abstract

“…[10][11][12][13] An expensive high-end instrument is used in the echocardiographic laboratory, operated by a skilled sonographer and supervised by experienced physicians. Echocardiographic examination is, therefore, performed several days after the initial physician-patient encounter.…”

Section: Discussionmentioning

confidence: 99%

Pocket-Sized Transthoracic Echocardiography Device for the Measurement of Cardiac Chamber Size and Function

Fukuda

Shimada

Kawasaki

et al. 2009

Circ J

View full text Add to dashboard Cite

echnological advances in electronic miniaturization have resulted in the creation of small, portable transthoracic echocardiographic (pTTE) devices. The major advantage of a portable device is being able to provide immediate information both within and, for the first time, outside the hospital setting. Previous studies have reported that pTTE is superior to physical examination, and comparable with complete standard TTE (sTTE) as a diagnostic tool in clinical practice. 1-3 Physical examination is recognized as an initial screening method, but the skill set required to perform physical examinations has unfortunately deteriorated over the past 2 decades as medical technology has advanced. 4-6 Therefore, visualizing the heart as well as being able to calculate limited quantitative measurements of the cardiac chambers and their function, may result in improved patient care and/or understanding.Compared with a stethoscope, previous portable devices were too large and heavy (≈2.5 kg) for physicians to carry while making rounds. A pocket-sized imaging device has better portability and agility, enhancing the use of pTTE. 7 We investigated the feasibility and accuracy of pTTE for assessing cardiac chamber size and function. Methods Study PopulationThe study group consisted of 125 unselected patients (70 males, mean age 70±13 years) who were scheduled for sTTE to evaluate left ventricular (LV) function: 65 patients with coronary artery disease (24 with a history of myo- (Received November 18, 2008; revised manuscript received January 27, 2009; accepted January 28, 2009; released online April 16, 2009

show abstract

Subclinical Left Ventricular Longitudinal Systolic Dysfunction in Hypertension With No Evidence of Heart Failure

Cited by 50 publications

References 23 publications

Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy

Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy

Elevated E/E' Predicts Prognosis in Congestive Heart Failure Patients With Preserved Systolic Function

Pocket-Sized Transthoracic Echocardiography Device for the Measurement of Cardiac Chamber Size and Function

Contact Info

Product

Resources

About